Development of a transferrin receptor-targeting HVJ-E vector

Biochemical and Biophysical Research Communications

Volumn 364, Issue 3, 2007, Pages 423-428

  Shimbo, Takashi ^a   Kawachi, Masako ^a   Saga, Kotaro ^a   Fujita, Hiroshi ^a   Yamazaki, Takehiko ^a   Tamai, Katsuto ^a   Kaneda, Yasufumi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer therapy; HVJ E; Targeting; Transferrin

Indexed keywords

HN PROTEIN; SIALIC ACID; SMALL INTERFERING RNA; TRANSFERRIN; TRANSFERRIN F PROTEIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CELL LINE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; HOST CELL; HUMAN; HUMAN CELL; NONHUMAN; PARAINFLUENZA VIRUS 1; PRIORITY JOURNAL;

ANIMALS; CELL LINE; DRUG DELIVERY SYSTEMS; GENE TARGETING; GENETIC VECTORS; HELA CELLS; HUMANS; KIDNEY; MICE; MICE, NUDE; SENDAI VIRUS; TRANSFECTION; TRANSFERRIN;

SENDAI VIRUS;

EID: 35648993476     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.09.135     Document Type: Article

References (27)

1. Cavallari A., and Amadori D. Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis. J. Surg. Oncol. 87 (2004) 46-52
2. Smith R.E., Colangelo L., Wieand H.S., Begovic M., and Wolmark N. Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. JNCI 96 (2004) 1128-1132
3. McMillan T.J., and Hart I.R. Can cancer chemotherapy enhance the malignant behaviour of tumours?. Cancer Metastasis Rev. 6 (1987) 503-520
4. Dass C. Immunostimulatory activity of cationic-lipid-nucleic-acid complexes against cancer. J. Cancer. Res. Clin. Oncol. 128 (2002) 177-181
5. Mandal M., and Lee K.D. Listeriolysin O-liposome-mediated cytosolic delivery of macromolecule antigen in vivo: enhancement of antigen-specific cytotoxic T lymphocyte frequency, activity, and tumor protection. Biochim. Biophys. Acta 1563 (2002) 7-17
6. Kaneda Y., Nakajima T., Nishikawa T., Yamamoto S., Ikegami H., Suzuki N., Nakamura H., Morishita R., and Kotani H. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol. Ther. 6 (2002) 219-226
7. Ito M., Yamamoto S., Nimura K., Hiraoka K., Tamai K., and Kaneda Y. Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J. Gene Med. 7 (2005) 1044-1052
8. Mima H., Yamamoto S., Ito M., Tomoshige R., Tabata Y., Tamai K., and Kaneda Y. Targeted chemotherapy against intraperitoneally disseminated colon carcinoma using a cationized gelatin-conjugated HVJ envelope vector. Mol. Cancer Ther. 5 (2006) 1021-1028
9. Nishikawa T., Nakagami H., Matsuki A., Maeda A., Yo C.Y., Harada T., Morishita R., Tamai K., and Kaneda Y. Development of high-throughput functional screening of therapeutic genes, using a hemagglutinating virus of Japan envelope vector. Hum. Gene Ther. (2006)
10. Yasuoka E., Oshima K., Tamai K., Kubo T., and Kaneda Y. Needleless intranasal administration of HVJ-E containing allergen attenuates experimental allergic rhinitis. J. Mol. Med. (2006)
11. Fujihara A., Kurooka M., Miki T., and Kaneda Y. Eradication of renal cell carcinoma in mice mediated by NK cell activation using inactivated Sendai virus particle (HVJ-E). Mol. Ther. 13 (2006) S107
12. Kurooka M., and Kaneda Y. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res. 67 (2007) 227-236
13. Okada Y. Sendai virus-induced cell fusion. Methods Enzymol. 221 (1993) 18-41
14. Kawachi M., Tamai K., Saga K., Yamazaki T., Fujita H., Shimbo T., Nimura K., Nishifuji K., Amagai M., Uitto J., and Kaneda Y. Development of tissue-targeting HVJ envelope vector for successful delivery of therapeutic gene to mouse skin. Hum. Gene Ther. 18 (2007) 881-894
15. Taira H., Ranin L., and Iwasaki K. Construction of expression plasmids for the fusion protein of Sendai virus, and their expression in E. coli cells and eucaryotic cells. FEBS Lett. 262 (1990) 39-41
16. Niwa H., Yamamura K., and Miyazaki J. Efficient selection for high expression transfectants with a novel eukaryotic vector. Gene 108 (1991) 193-199
17. Everts M., and Curiel D.T. Transductional targeting of adenoviral cancer gene therapy. Curr. Gene Ther. 4 (2004) 337-346
18. Jia W., and Zhou Q. Viral vectors for cancer gene therapy: viral dissemination and tumor targeting. Curr. Gene Ther. 5 (2005) 133-142
19. Amiji M.M. Polymeric Gene Delivery: Principles and Applications (2004), CRC Press
20. Ishida O., Maruyama K., Tanahashi H., Iwatsuru M., Sasaki K., Eriguchi M., and Yanagie H. Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm. Res. 18 (2001) 1042-1048
21. Daniels T.R., Delgado T., Rodriguez J.A., Helguera G., and Penichet M.L. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin. Immunol. 121 (2006) 144-158
22. Iinuma H., Maruyama K., Okinaga K., Sasaki K., Sekine T., Ishida O., Ogiwara N., Johkura K., and Yonemura Y. Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int. J. Cancer 99 (2002) 130-137
23. Qian Z.M., Li H., Sun H., and Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharm. Rev. 54 (2002) 561-587
24. Derycke A.S.L., Kamuhabwa A., Gijsens A., Roskams T., De Vos D., Kasran A., Huwyler J., Missiaen L., and de Witte P.A.M. Transferrin-conjugated liposome targeting of photosensitizer AlPcS4 to rat bladder carcinoma cells. JNCI 96 (2004) 1620-1630
25. Xu L., Tang W.H., Huang C.C., Alexander W., Xiang L.M., Pirollo K.F., Rait A., and Chang E.H. Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv. Mol. Med. 7 (2001) 723-734
26. Xu L., Pirollo K.F., and Chang E.H. Transferrin-liposome-mediated p53 sensitization of squamous cell carcinoma of the head and neck to radiation in vitro. Hum. Gene. Ther. 8 (1997) 467-475
27. Xu L., Pirollo K.F., and Chang E.H. Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy. J. Control. Release 74 (2001) 115-128